EVAX

AI Memo

Evaxion A/S

As of 2026-06-18/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

EVX-01 three-year phase 2 data remains the main binary readout • 2026-09-30

Base target: $3 / p=45% prob

Biggest risk

The bear case is that this is still a thinly covered micro-cap biotech with no operating revenue, limited external validation in the packet, and a thesis that depends heavily on future readouts and business-development execution rather than on current fundamentals. A slip in EVX-01 data timing, EVX-04 filing progress, or partnering could quickly refocus investors on dilution risk.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The constructive case is that EVX-01 already shows immunogenicity support, the three-year follow-up can extend durability evidence, EVX-04 provides a second pipeline checkpoint, and management is explicitly pursuing partnership discussions that could reduce reliance on equity funding [#PR-2026-05-07] [#PR-2026-05-12].

Research note

Recommendation

—

Confidence

medium

As of

2026-06-18

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Partnering progress could matter more than quarterly P&L
The constructive case is that EVX-01 already shows immunogenicity support, the three-year follow-up can extend durability evidence, EVX-04 provides a second pipeline checkpoint, and management is explicitly pursuing partnership discussions that could reduce reliance on equity funding [#PR-2026-05-07] [#PR-2026-05-12].
The packet shows a median target of $11.75 but the analyst count is unavailable, so that figure should not be treated as reliable consensus.

BearKey bullets

Cash and cash equivalents fell to $18.4 million at March 31, 2026 from $23.2 million at December 31, 2025, even though management still guides runway into the second half of 2027 [#PR-2026-05-07].
Forward visibility is limited because coverage is sparse and the evidence packet lacks usable SEC filing excerpts or broad post-print analyst revision data.
Peer set quality is loose, which lowers confidence in relative valuation comparisons and makes the name more dependent on company-specific catalyst outcomes.

WatchKey bullets

EVX-01 three-year phase 2 data remains the main binary readout

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $3 (p=45%)

Target spread vs base: +87% / -53%

Scenario probabilities

Bull Target: $6 (p=25%)Base Target: $3 (p=45%)Bear Target: $2 (p=30%)

Commentary

This remains a cautious monitoring setup, not a high-conviction call. Primary company materials support real 2026 milestones, but independent coverage is thin, there is no usable analyst-revision tape in the packet, and the deterministic prior remains negative with very low evidence quality. The stock is therefore more likely to trade on EVX-01 durability data, EVX-04 execution, and any partnering headlines than on conventional earnings mechanics.

As of 2026-06-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Partnering progress could matter more than quarterly P&L

Scenarios

Bull Target (Scenario probability)

$6 / p=25% prob

Base Target (Scenario probability)

$3 / p=45% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Analysis 2026-06-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
EVX-01 three-year phase 2 data remains the main binary readout
Evaxion said it completed the one-year extension of the phase 2 EVX-01 study, with last-patient last-visit in April, and expects to present three-year data in the second half of 2026; for a micro-cap biotech with limited commercial revenue, this remains the clearest value-setting catalyst [#PR-2026-05-07].
Prob 60.00% • Move 24.00% • Priced-in 35.00%
EVENT2026-12-31
EVX-04 clinical-trial application target in H2 2026
Company materials said EVX-04 preclinical work is intended to support a clinical trial application in the second half of 2026, giving investors a concrete execution checkpoint beyond EVX-01 and a test of whether the platform can advance a second oncology asset toward the clinic [#PR-2026-05-12].
Prob 50.00% • Move 18.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Partnering progress could matter more than quarterly P&L
2026-12-31
Management said it remains active in several parallel partnership discussions tied to interest in both the platform and pipeline, so any non-dilutive collaboration, licensing, or strategic-development update could matter disproportionately for sentiment and financing risk [#PR-2026-05-07].
Prob 35% • Move 20% • Priced-in 20%

Risks

Cash and cash equivalents fell to $18.4 million at March 31, 2026 from $23.2 million at December 31, 2025, even though management still guides runway into the second half of 2027 [#PR-2026-05-07].
Forward visibility is limited because coverage is sparse and the evidence packet lacks usable SEC filing excerpts or broad post-print analyst revision data.
Peer set quality is loose, which lowers confidence in relative valuation comparisons and makes the name more dependent on company-specific catalyst outcomes.
The company reported zero revenue and a $3.6 million net loss in Q1 2026, so equity value still depends on pipeline progress and external funding or partnering support [#PR-2026-05-07].

Peers

Symbol	Summary
LSTA	Small oncology biotech comp with similar micro-cap, milestone-driven trading behavior; more useful for event-risk framing than as a direct platform peer.
SNTI	Another sub-scale biotech where clinical updates and capital-markets access can dominate equity performance; relevant mainly for financing and catalyst volatility context.
APLM	Clinical-stage oncology biotech comparator with binary development milestones, though the scientific approach is different and the peer fit is loose.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-18

Loading AI feed…

Symbol

Summary

LSTA

Small oncology biotech comp with similar micro-cap, milestone-driven trading behavior; more useful for event-risk framing than as a direct platform peer.

SNTI

Another sub-scale biotech where clinical updates and capital-markets access can dominate equity performance; relevant mainly for financing and catalyst volatility context.

APLM

Clinical-stage oncology biotech comparator with binary development milestones, though the scientific approach is different and the peer fit is loose.